Sareum Holdings PLC Sierra Oncology to host call on Chk1 inhibitor (0247R)
18 September 2017 - 9:00PM
UK Regulatory
TIDMSAR
RNS Number : 0247R
Sareum Holdings PLC
18 September 2017
(AIM: SAR) 18 September 2017
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sierra Oncology to host Key Opinion Leader call with Thomas
Helleday, PhD on DNA Damage Response Targets, on Tuesday 19
September
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, notes that Sierra Oncology, the
licence holder advancing clinical cancer candidate SRA737, will
host a Key Opinion Leader call with Thomas Helleday, PhD on the
topic of "DNA Damage Response Targets Beyond PARP" focusing on
clinical stage DDR targets in oncology, including Checkpoint kinase
1 (Chk1), on Tuesday, September 19 at 10:30 am Eastern Time (3:30pm
UK time) - details below.
SRA737 is a potent, highly selective, orally bioavailable small
molecule inhibitor of Chk1, a key regulator of important cell cycle
checkpoints and central mediator of the DNA damage Response (DDR)
network. Sierra Oncology holds exclusive and worldwide rights for
SRA737, having licensed the programme from Sareum's co-investment
partner, the CRT Pioneer Fund, in September 2016. SRA737 is
currently being investigated in two Phase 1 clinical trials in
patients with advanced cancer.
The call will feature a presentation by distinguished scientist
Thomas Helleday, PhD, the Torsten and Ragnar Söderberg Professor of
Translational Medicine and Chemical Biology at Karolinska
Institutet, Stockholm, Sweden, who will examine emerging data and
current mechanistic understandings of the next generation of
clinical stage DDR targets in oncology, including Chk1. In
addition, he will review which drug targets are synergistic in
combination with Chk1 inhibition, and also will discuss certain
preclinical DDR targets currently generating interest in the
field.
Sierra Oncology's Senior Vice President of Research, Christian
Hassig, PhD, will provide a brief overview on the company's
research and development strategy for SRA737, which has
best-in-class potential and is currently in two Phase 1 clinical
trials focused on enrolling patients with tumours identified to
have genetic aberrations hypothesized to confer sensitivity to Chk1
inhibition via synthetic lethality, as a monotherapy or in
combination.
The Press release from Sierra Oncology can be found by clicking
here
Dial-In & Webcast Information
Domestic: +1 800-289-0496
International: +1 719-325-4826
Conference ID: 8310106
Webcast: www.sierraoncology.com
direct link: http://public.viavid.com/index.php?id=126208
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKVLBFDKFLBBL
(END) Dow Jones Newswires
September 18, 2017 07:00 ET (11:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024